Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis. Issue 12 (December 2014)

• Record Type: Journal Article
• Authors: Liu, Wen-Jian; Tan, Xiao-Hong; Luo, Xiu-Ping; Guo, Bao-Ping; Wei, Zhou-Ji; Ke, Qing; He, Sha; Cen, Hong
• Is Part Of: Leukemia & lymphoma. Volume 55:Issue 12(2014:Dec.)
• Page Start: 2691
• Page End: 2698
• Publication Date: 2014-12
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.893308
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>Tet methylcytosine dioxygenase 2 (<italic>TET2</italic>) gene mutations have recently been recognized in acute myeloid leukemia (AML). We performed a meta-analysis to evaluate the controversial prognostic significance of <italic>TET2</italic> mutations in AML. Eight studies, covering 2552 patients with AML, were included in this analysis. Pooled hazard ratios (HRs) indicated that <italic>TET2</italic> mutations had a poor prognostic impact on the survival of patients with AML. The combined HR for overall survival (OS) was 1.53 and the summary HR for event-free survival (EFS) was 1.64. Additionally, <italic>TET2</italic> mutations appeared to be an adverse prognostic indicator in both patients with cytogenetically normal (CN)-AML (HR for OS: 1.43 and HR for EFS: 1.76) and subgroups of patients with favorable-risk genotypes (HR for EFS: 2.35) and intermediate-I-risk genotypes (HR for EFS: 1.57). These findings indicate that <italic>TET2</italic> mutations have an adverse impact on prognosis and may help to justify risk-adapted therapeutic strategies for patients with AML.</p> </abstract>